Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination

Published:2008-01 Issue:12 Volume:49 Page:2333-2343
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Åleskog Anna,Norberg Maria,Nygren Peter,Rickardson Linda,Kanduri Meena,Tobin Gerard,Åberg Magnus,Gustafsson Mats G.,Rosenquist Richard,Lindhagen Elin

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10428190802475295

Reference26 articles.

1. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.

2. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies

3. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway

4. Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer

5. Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Mechanical Autophagy as a Part of Cellular Immunity; Facts and Features in Treating the Medical Disorders;Immunological Investigations;2020-09-29

2. Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells;Leukemia & Lymphoma;2018-11-08

3. The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model;Blood;2015-06-25

4. Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies;British Journal of Haematology;2014-05-19

5. The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia;Blood;2012-01-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3